unlocking value
from innovation
Looking for assets?
We regularly encounter promising early-stage projects through our relationships with academic researchers, founders, and emerging biotech teams. By engaging early and building long-term mentoring relationships, we develop a deeper understanding of both the science and the people behind each opportunity.
This enables us to help shape the investment case over time—clarifying the problem being addressed, strengthening the proposed solution, sharpening differentiation, and aligning the narrative with the priorities of biotech-focused VCs and corporate investors. It is a journey rather than a one-off exercise.
Looking for a CMC expert?
A VC has backed a promising asset, but its CMC and development plan needs strengthening. Hiring a full-time CMC lead may be premature, too costly, or unsuitable for the company’s current stage.
We provide experienced CMC leadership for the asset or portfolio company—defining a realistic development path, planning clinical supply, engaging CDMOs and regulators, and preparing clear updates for boards and investors. We distinguish what needs to happen now, what can wait, and where the key technical, supply, and timeline risks lie.
The result is a clearer plan, fewer surprises, and a more credible investment case—without the cost or commitment of a full-time hire.
Looking to buy?
When a private-equity firm or corporate buyer considers a carve-out, site acquisition, or platform purchase, technical and CMC risks can significantly affect the value and success of the transaction. We support investors throughout the process—from initial due diligence through post-close integration and transition.
We assess the target’s technical capabilities, facilities, quality systems, manufacturing processes, and supply-chain resilience. We identify what may be difficult, costly, or time-consuming to transfer or improve, and provide practical, evidence-based plans to mitigate these risks.
Following completion, we help integrate the asset into the buyer’s operations by aligning quality systems, managing CDMO transitions, and safeguarding continuity of clinical or commercial supply. The result is a clearer view of value, fewer post-deal surprises, and a more controlled path to execution.